Intetumumab Explained

Intetumumab is a human monoclonal antibody targeting integrins[1] that was being studied for the treatment of solid tumors.[2]

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[3]

References

  1. Łasiñska I, Mackiewicz J . Integrins as A New Target for Cancer Treatment . Anti-Cancer Agents in Medicinal Chemistry . 19 . 5 . 580–586 . 2019 . 30451118 . 10.2174/1871520618666181119103413 . 53952455 .
  2. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab. American Medical Association.
  3. Web site: Intetumumab. AdisInsight. 30 January 2017.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Intetumumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.